{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:28:32Z","timestamp":1761805712341,"version":"build-2065373602"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"\n Background<\/jats:title>\n Focal Segmental Glomerulosclerosis (FSGS) is a common aetiology of nephrotic syndrome and a leading cause of end-stage renal disease. Corticosteroid therapy is considered the first-line treatment in patients with proteinuria, but it carries a heterogeneous range of common and rare complications.<\/jats:p>\n <\/jats:sec>\n \n Case summary<\/jats:title>\n We report the case of a 19-year-old patient, recently diagnosed with FSGS secondary to anabolic steroid use and receiving glucocorticoid therapy, who presented to our emergency department with acute respiratory distress and neck swelling. He was subsequently diagnosed with pneumomediastinum and acute bilateral saddle pulmonary embolism (PE).<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n The rare occurrence of FSGS treated with glucocorticoid therapy, complicated by severe thromboembolic events and pneumomediastinum, emphasizes the complexity of managing the treatment of a young patient by balancing the risks and benefits and tailoring the dosage to achieve maximal therapeutic effect with minimal adverse events.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Close monitoring should be provided to patients with a procoagulant status due to nephrotic syndrome, as well as to those at additional risk from corticosteroid treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1670155","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:24:05Z","timestamp":1761805445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Pneumomediastinum and pulmonary embolism in a 19-year-old with focal segmental glomerulosclerosis: a rare double-complication of corticosteroid therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Demetra Emanuela","family":"Rotaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Achim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","article-title":"Focal segmental glomerulosclerosis","volume-title":"StatPearls","author":"Rout","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The pathogenesis of focal segmental glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1681\/ASN.2009040450","article-title":"Development of focal segmental glomerulosclerosis after anabolic steroid abuse","volume":"21","author":"Herlitz","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11606-021-06751-3","article-title":"Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review","volume":"36","author":"Bonnecaze","year":"2021","journal-title":"J Gen Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"M11","DOI":"10.1530\/EJE-15-0198","article-title":"Adverse effects of glucocorticoids: coagulopathy","volume":"173","author":"Coelho","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/JU.0000000000002437","article-title":"Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy","volume":"207","author":"Ory","year":"2022","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1378\/chest.12-1446","article-title":"Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study","volume":"143","author":"Stuijver","year":"2013","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/2229-5151.183019","article-title":"Nephrotic syndrome-induced thromboembolism in adults","volume":"6","author":"Al-Azzawi","year":"2016","journal-title":"Int J Crit Illn Inj Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2023.0354","article-title":"Thromboembolic phenomena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment","volume":"85","author":"Wang","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000168196","article-title":"Coagulation factors in nephrotic syndrome","volume":"10","author":"Kanfer","year":"1990","journal-title":"Am J Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2169\/internalmedicine.6892-20","article-title":"Predictive factors for pneumomediastinum during management of connective tissue disease-related interstitial lung disease: a retrospective study","volume":"60","author":"Okamoto","year":"2021","journal-title":"Intern Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.3978\/j.issn.2072-1439.2015.01.11","article-title":"Pneumomediastinum","volume":"7","author":"Kouritas","year":"2015","journal-title":"J Thorac Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2147\/JIR.S389839","article-title":"Spontaneous pneumomediastinum and subcutaneous emphysema in dermatomyositis: a case series and literature review","volume":"16","author":"Subki","year":"2023","journal-title":"J Inflamm Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.55729\/2000-9666.1002","article-title":"A dangerous duo: spontaneous pneumomediastinum and venous thromboembolism at presentation in a patient with COVID-19 pneumonia","volume":"12","author":"Nasirova","year":"2022","journal-title":"J Community Hosp Intern Med Perspect"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1670155\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:24:07Z","timestamp":1761805447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1670155\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":15,"alternative-id":["10.3389\/fcvm.2025.1670155"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1670155","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1670155"}}